TELA Bio Statistics
Total Valuation
TELA Bio has a market cap or net worth of $50.34 million. The enterprise value is $64.20 million.
Important Dates
The last earnings date was Thursday, November 13, 2025, after market close.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TELA Bio has 43.77 million shares outstanding. The number of shares has increased by 78.98% in one year.
| Current Share Class | 43.77M |
| Shares Outstanding | 43.77M |
| Shares Change (YoY) | +78.98% |
| Shares Change (QoQ) | +0.12% |
| Owned by Insiders (%) | 8.16% |
| Owned by Institutions (%) | 32.10% |
| Float | 20.91M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.66 |
| Forward PS | 0.56 |
| PB Ratio | 29.80 |
| P/TBV Ratio | 488.73 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.83 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.30, with a Debt / Equity ratio of 27.99.
| Current Ratio | 3.30 |
| Quick Ratio | 2.41 |
| Debt / Equity | 27.99 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.25 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -38.68% |
| Return on Invested Capital (ROIC) | -54.16% |
| Return on Capital Employed (ROCE) | -79.49% |
| Revenue Per Employee | $368,684 |
| Profits Per Employee | -$186,593 |
| Employee Count | 209 |
| Asset Turnover | 1.34 |
| Inventory Turnover | 1.98 |
Taxes
| Income Tax | -59,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -60.21% in the last 52 weeks. The beta is 0.87, so TELA Bio's price volatility has been lower than the market average.
| Beta (5Y) | 0.87 |
| 52-Week Price Change | -60.21% |
| 50-Day Moving Average | 1.32 |
| 200-Day Moving Average | 1.57 |
| Relative Strength Index (RSI) | 44.85 |
| Average Volume (20 Days) | 351,775 |
Short Selling Information
The latest short interest is 416,541, so 0.95% of the outstanding shares have been sold short.
| Short Interest | 416,541 |
| Short Previous Month | 485,110 |
| Short % of Shares Out | 0.95% |
| Short % of Float | 1.99% |
| Short Ratio (days to cover) | 2.45 |
Income Statement
In the last 12 months, TELA Bio had revenue of $77.06 million and -$39.00 million in losses. Loss per share was -$0.89.
| Revenue | 77.06M |
| Gross Profit | 52.19M |
| Operating Income | -35.46M |
| Pretax Income | -39.06M |
| Net Income | -39.00M |
| EBITDA | -34.41M |
| EBIT | -35.46M |
| Loss Per Share | -$0.89 |
Full Income StatementBalance Sheet
The company has $29.71 million in cash and $43.57 million in debt, giving a net cash position of -$13.86 million or -$0.32 per share.
| Cash & Cash Equivalents | 29.71M |
| Total Debt | 43.57M |
| Net Cash | -13.86M |
| Net Cash Per Share | -$0.32 |
| Equity (Book Value) | 1.56M |
| Book Value Per Share | 0.04 |
| Working Capital | 39.07M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$30.88 million and capital expenditures -$621,000, giving a free cash flow of -$31.50 million.
| Operating Cash Flow | -30.88M |
| Capital Expenditures | -621,000 |
| Free Cash Flow | -31.50M |
| FCF Per Share | -$0.72 |
Full Cash Flow StatementMargins
Gross margin is 67.73%, with operating and profit margins of -46.02% and -50.61%.
| Gross Margin | 67.73% |
| Operating Margin | -46.02% |
| Pretax Margin | -50.69% |
| Profit Margin | -50.61% |
| EBITDA Margin | -44.66% |
| EBIT Margin | -46.02% |
| FCF Margin | n/a |
Dividends & Yields
TELA Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -78.98% |
| Shareholder Yield | -78.98% |
| Earnings Yield | -77.47% |
| FCF Yield | -62.58% |
Analyst Forecast
The average price target for TELA Bio is $3.31, which is 187.83% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.31 |
| Price Target Difference | 187.83% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | 16.79% |
| EPS Growth Forecast (5Y) | -52.72% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TELA Bio has an Altman Z-Score of -7.94 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -7.94 |
| Piotroski F-Score | 3 |
